Marissa Fiorentino

Data from the CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC.

The FDA granted priority review to EV plus pembrolizumab as a perioperative regimen for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS events, a 35% reduction in the risk of death, and a pCR rate of 55.8% vs 32.5% with standard chemotherapy.